lol. free means gov subsidy buy from all the distributor like dph and ph..but it is ok since here is public forum. many gloves holder see vaccine is big threat for them.
Pfizer and BioNTech’s favored Covid-19 vaccine has fewer side effects than their first
(PUBLISHED THU, AUG 20 20208:17 PM EDT)
Pfizer and BioNTech surprised many industry watchers on July 27 when they announced they would conduct a large-scale study of a vaccine for Covid-19. The surprise? The vaccine that would be tested in a 30,000-patient trial wasn’t the one for which the companies had presented data on July 1.
The reason, the companies said, was that a second vaccine seemed to generate a similar immune response, but fewer side effects. On Thursday, they posted the results from all 332 people who received either vaccine, referred to as vaccines B1 or B2 — and indeed, B2 recipients experienced markedly fewer adverse events tied to the vaccine.
“Obviously, the better tolerated the vaccine, the more I think it will encourage public acceptance of a broad immunization,” said William Gruber, the senior vice president of vaccine clinical research and development at Pfizer. “Both would have been great candidates. We were fortunate that B2 actually satisfied having both a favorable immune profile and fewer reactions.”
The study tested doses of each vaccine ranging from 10 micrograms to 100 micrograms. The 30-microgram dose of B2 is being taken forward in clinical trials.
With the original vaccine, called BNT162b1, or B1 for short, patients between the ages of 18 and 55 had adverse events thought to be related to the vaccine 50% of the time at the 30-microgram dose. Those between the ages of 65 and 85 had related adverse events 16.7% of the time.
For the second vaccine, BNT162b2, or B2, patients between 18 and 55 had adverse events thought to be related to the vaccine 16.7% of the time, and no adverse effects thought to be related to the vaccine were reported in those between the ages of 65 and 85.
Both vaccines use mRNA — the genetic messenger the body uses to make the DNA code into proteins — packaged inside a fatty capsule, called a lipid nanoparticle, that allows it to get into cells. The mRNA instructs cells to make a protein, which then triggers the immune system into action. For the B1 vaccine, the mRNA coded for the part of a protein on the SARS-CoV-2 virus that binds to a receptor on human cells in order to gain entry to them. The B2 vaccine makes the entirety of this protein, known as the spike protein.
Using the full spike protein may allow the immune system to figure out more ways to detect and attack the virus. Chemical modifications to the mRNA may also explain some of the difference. Although the same dosage, by weight, was given to patients with each vaccine, the B2 vaccine would include fewer particles, because the full-length mRNA is heavier.
The side effects tracked were mostly those one would expect from a vaccine injection, including soreness at the injection site, fever, chills, headache, and muscle or joint pain. No older adult who received B2 reported redness or swelling at the injection site.
The average level of antibodies to the virus in older adults was only 41% that seen in younger participants. However, it was still higher than the level of antibodies seen in recovered patients, the authors said.
All patients in the study of B2 were white and non-Hispanic, with more older women than older men participating. The younger patients were a median of 37 years old, while the older ones were a median of 69.
Pfizer has said that some data from its large study of the B2 vaccine could come as early as October.
KUALA LUMPUR (Aug 21): MIDF Amanah Investment Bank Bhd and Kenanga Investment Bank Bhd are among research firms which had today raised their share target prices (TPs) for Pharmaniaga Bhd in anticipation of earnings growth as the company is seen as the frontrunner to secure the Malaysian government's contract to repackage and distribute the Covid-19 vaccine.
MIDF said today it had revised its Pharmaniaga TP to RM4.74 from the previously-estimated RM3.15. Kenanga said its Pharmaniaga TP is raised to RM1.80 from RM1.35.
Old outdated news lah...Dpharma & Pharmaniaga need to rely on western vaccine loh....!!
For the West they themselves also not enough mah....just look at USA highest Covid19 case in the world loh...!!
Thus it will take a long time to reach msia loh...by then Covid19 epidemic over liao mah....!!
Solution cansino vaccine very steady loh...can easily ramp up so more loh....!!
U look at the price upgrade lah...!!
Pharmaniaga price now Rm 4.34 upgrade to tp Rm 1.80 means more to fall by Rm 2.54 or fall of another 58% loh...!! Better lari kuat kuat b4 too late mah...!!
Posted by DrLimKH > Aug 21, 2020 6:17 PM | Report Abuse
KUALA LUMPUR (Aug 21): MIDF Amanah Investment Bank Bhd and Kenanga Investment Bank Bhd are among research firms which had today raised their share target prices (TPs) for Pharmaniaga Bhd in anticipation of earnings growth as the company is seen as the frontrunner to secure the Malaysian government's contract to repackage and distribute the Covid-19 vaccine.
MIDF said today it had revised its Pharmaniaga TP to RM4.74 from the previously-estimated RM3.15. Kenanga said its Pharmaniaga TP is raised to RM1.80 from RM1.35.
have explained before why only pharmaniaga will get the contract and not even Dpharma...Ph already had 5y LD contract and is the only one with LD infra
Datuk Seri Ismail Sabri Yaakob confirmed last night that he received a letter of support from Deputy Defence Minister Ikmal Hisham Abdul Aziz purportedly asking for his son to be appointed to Pharmaniaga’s board of directors.
So Monday is goreng or drop? See how market decide.
Solution & Titijaya can Bungkus- or rather Ta Pau- Pump & Dump Stocks. --------------------------------- Pharmaniaga - D Pharma are the frontrunners. MOH will decide on the company not China.
Pharmaniaga TP upped as co deemed frontrunner in Covid-19 vaccine race TheEdge Fri, Aug 21, 2020 02:53pm - 23 hours ago
KUALA LUMPUR (Aug 21): MIDF Amanah Investment Bank Bhd and Kenanga Investment Bank Bhd are among research firms which had today raised their share target prices (TPs) for Pharmaniaga Bhd in anticipation of earnings growth as the company is seen as the frontrunner to secure the Malaysian government's contract to repackage and distribute the Covid-19 vaccine.
MIDF said today it had revised its Pharmaniaga TP to RM4.74 from the previously-estimated RM3.15. Kenanga said its Pharmaniaga TP is raised to RM1.80 from RM1.35.
---------------------------------------------- Posted by stockraider > Aug 22, 2020 1:38 PM | Report Abuse
List of vaccine players; - the dreamers.
1.Top number 1 Cansino with Solution as Distributor Nov vaccine available
2. Sinopharm with Titijaya as distributor { about 2 mths behind cansino}
Cansino management are military people...they are no nonsense people...they want best...they definately wont give a fxxk about solution loh...!!
Correctloh....thats why Cansino covid19 vaccine use by China military are no joke & not fruit juice sure wont give some cat dog company handle loh...!!
This is the world best quality vaccine u can find mah...!!
Cansino probably dont even know they got chosen by Solution as a partner mah...!
They dont even know who Solution is mah...!
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
MQ Trader 671 views | 3 d ago
0:17
New IPO: An enterprise IT solutions provider that provides implementation services, maintenance, support and professional services, Vetece Holdings Bhd aims to list on the Ace Market!
MQ Trader 656 views | 7 d ago
0:17
New IPO: A manufacturing and trading of biomass fuel products, particularly PKS and wood pellets company, Elridge Energy Holdings Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
James89
478 posts
Posted by James89 > 2020-08-21 09:28 | Report Abuse
Aiyoooo. Drop so little. Thought can drop till 2.8. Many glove barking here you guys scared of vaccine is it?